102 results on '"Valentino, L. A."'
Search Results
2. Recent Advances in the Treatment of Hemophilia: A Review
3. Laboratory variability in the diagnosis of type 2 VWD variants
4. PB0191 myGTR: A Patient Engagement Tool from the World Federation of Hemophilia Gene Therapy Registry
5. OC 20.5 The WFH Gene Therapy Registry: A Collaborative Approach Towards a Global Resource for the Long-Term Follow-up of People with Hemophilia Treated with Gene Therapy
6. PB0649 Results from the RESIST Study for Tolerance Induction in Patients with Poor Prognosis for ITI Success
7. In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents
8. Graphene-enhanced Raman scattering on single layer and bilayers of pristine and hydrogenated graphene
9. Towards the evaluation of defects in MoS2 using cryogenic photoluminescence spectroscopy
10. Complications of Methylene Blue Dye in Breast Surgery: Case Reports and Review of the Literature
11. Personalization of treatment regimens for active patients: a comparison of factor VIII and extended half-life treatment regimens: OR211
12. Reversible Lectin Binding to Glycan-Functionalized Graphene
13. The interview issue
14. Graphene-enhanced Raman scattering on single layer and bilayers of pristine and hydrogenated graphene
15. Towards the evaluation of defects in MoS2 using cryogenic photoluminescence spectroscopy
16. The use of sample positioning to control defect creation by oxygen plasma in isotopically labelled bilayer graphene membranes
17. Safety and pharmacokinetics of three doses of a new recombinant human Factor Vlla (LR769) in congenital hemophilia A or B patients: PO 295
18. Pharmacodynamic effects of escalating dosages of a new recombinant human Factor VIIa (LR769) in congenital hemophilia A or B patients: PO 291
19. Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A: PO 160
20. Peak FVIII levels and time spent in hemostatically effective FVIII range post-infusion correlates with improved efficacy for prophylaxis in hemophilia A: a closer look at the other end of the curve: PB 4.39–1
21. Hemostatic effect of an anti-TFPI peptide in a murine model of hemophilic joint bleeding: PB 3.58–3
22. Qualitative findings contributing to the development of a hemophilia-specific caregiver burden instrument: caregiver and health care professional insights: PB 3.38–5
23. The relationship between specific annual bleed rates and health outcomes among children with severe hemophilia A: PB 3.38–2
24. Pharmacokinetic results from a Phase I/III study of a novel recombinant single-chain factor VIII (rVIII- SingleChain) compared to octocog alfa in severe haemophilia A patients: PB 2.55–4
25. Bleeding pattern and median time interval between bleeding episodes amongst patients receiving on - demand and prophylaxis therapy: PB 2.37–2
26. Treatment of bleeding episodes in subjects with haemophilia B with the long-lasting recombinant factor IX Fc fusion protein (rFIXFc) in the phase 3 B-LONG study: PA 2.07–6
27. Clinical implications of population pharmacokinetics of rFIXFc in routine prophylaxis, control of bleeding and perioperative management for haemophilia B patients: PA 2.07–5
28. B-LONG: results from a Phase 3 study of safety, efficacy, and pharmacokinetics of long-lasting recombinant factor IX Fc Fusion Protein (rFIXFc): OC 70.1
29. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management
30. P171 Catastrophic systemic multiple embolism from a giant atrial mixoma: a case report
31. Blood-induced joint disease: the pathophysiology of hemophilic arthropathy
32. Selective self-assembly and light emission tuning of layered hybrid perovskites on patterned graphene
33. Hemostatic effect of recombinant factor VIIa, NN1731 and recombinant factor VIII on needle-induced joint bleeding in hemophilia A mice
34. Implications of TiO2 surface functionalization on polycrystalline mixed halide perovskite films and photovoltaic devices
35. Life expectancy in hemophilia outcome
36. Strategies for preventing group B streptococcal infections in newborns: A nation-wide survey of Italian policies
37. Fully Vapor-Deposited Heterostructured Light-Emitting Diode Based on Organo-Metal Halide Perovskite
38. Loss of coral reef growth capacity to track future increases in sea level
39. Loss of coral reef growth capacity to track future increases in sea level
40. Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis
41. Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis
42. Changes in physicochemical and transport properties of a reverse osmosis membrane exposed to chloraminated seawater
43. On probabilistic record linkage: New methods compared to the fellegi-sunter approach
44. Compact planar monopole for broad band applications
45. Valutazioni igienico-sanitarie delle acque in tre invasi artificiali della provincia di Palermo destinate al consumo umano
46. Use of RBS for understanding the impact of hypohalogenous acids on PA membrane
47. In vitrostudies show synergistic effects of a procoagulant bispecific antibody and bypassing agents
48. Effects of chloraminated seawater on the SW30HR reverse osmosis membrane
49. Change in performances and structure of RO membrane after chloramination in pure water, synthetic and natural seawater
50. Change in Performances and Structure of RO Membrane after Chloramination in Pure Water, Synthetic and Natural Seawater
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.